Health TrialsbyHealthPanel

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Participants needed: 64
Trial details
Phase: Phase 1, Phase 2Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Oct 6, 2026Locations: 31
Eligibility criteria

Histologically confirmed, ER+, HER2-negative, locally advanced and unresectable... [+8]

Prior radiopharmaceutical therapy, including radioembolization. [+8]

Read more
Status: Not yet recruiting

RYZ711 Diagnostic Platform Study

This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed adenocarcinoma of the prostate.

Participants needed: 116
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: RayzeBio, Inc.Updated: Oct 7, 2026
Eligibility criteria

Histologically confirmed adenocarcinoma of the prostate [+5]

eGFR < 60 mL/min, QTcF > 470 ms, impaired hepatic function [+5]

Read more
Status: Recruiting

Imaging Study in Metastatic Clear Cell RCC.

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).

Participants needed: 10
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Sep 29, 2026Locations: 4
Eligibility criteria

At least 18 years old at the time of signing the informed consent form (ICF). [+1]

Subjects taking below mentioned medications that cannot be stopped 5 half-lives... [+1]

Read more
Status: Recruiting

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Participants needed: 40
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Sep 29, 2026Locations: 4
Eligibility criteria

Are at least 18 years old at the time of signing the informed consent form (ICF) [+1]

For Women of Childbearing Potential: Are pregnant or breastfeeding

Read more
Status: Recruiting

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)

Participants needed: 590
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Sep 28, 2026Locations: 13
Eligibility criteria

Age of at least 18 years at the time of signing the informed consent form (ICF) [+17]

Subjects with fibrolamellar carcinoma, sarcomatoid HCC or combined hepatocellula... [+20]

Read more
Status: Recruiting

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Participants needed: 104
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: RayzeBio, Inc.Updated: Sep 15, 2026Locations: 14
Eligibility criteria

At least 18 years old at the time of signing the main study informed consent for... [+4]

Prior RPT, including Lu-177. [+7]

Read more